We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Global POC Coag Test Market Driven by Increasing Geriatrics

By LabMedica International staff writers
Posted on 03 May 2018
The global point-of-care (POC) coagulation testing market is projected to grow at a CAGR of over 6% during the period 2018-2022, driven by the growing geriatric population, worldwide, and increasing focus on personalized medicine. More...
These are the latest findings of Technavio Research, (London, UK), a global technology research and advisory company.

The aging population is increasing gradually across the world. In 2015, people over the age of 65 years comprised about 7-8% of the global population and are estimated to grow by 50-55% with 1.2-1.4 billion people likely to be aged above 65 years by 2030. This increase in the aging population is leading to the rising prevalence of lung disease, stroke, and cancer among people over the age of 65 years as their immune systems and functioning of organs become weaker and more susceptible to infections. This is driving an increase in the number of blood coagulation disorders, thereby propelling the demand for blood coagulation testing and POC coagulation analyzers.

Additionally, the development of whole genome technology, increasing number of retail clinics, and companion diagnostics are driving the demand for personalized medicine. The increasing focus on personalized medicine is expected to positively impact the POC coagulation testing market as the determination of coagulation in blood for providing the profiles of individual patients is crucial for developing personalized medicine. Hence, the demand for diagnostic instruments such as POC coagulation analyzers is increasing as they are used to diagnose and decide the appropriate treatments required for the disease.

Based on end-user, the hospitals and clinics segment accounted for the largest market share of more than 74% in 2017 and is expected to continue dominating the POC coagulation testing market during the forecast period. Geographically, the Americas led the global POC coagulation testing market in 2017 with the largest share of over 54%, followed by the EMEA and Asia Pacific. However, the Asia Pacific region will account for the largest market share during the forecast period, while the Americas and the EMEA will witness a slight decline in their market share over the same period.

Related Links:
Technavio Research


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.